Kyowa Kirin Co Ltd (4151) - Financial and Strategic SWOT Analysis Review
Kyowa Kirin Co Ltd (4151) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
Kyowa Kirin Co Ltd (Kyowa Kirin), a subsidiary of Kirin Holdings Co Ltd, is a research and development based biotechnology company. It focuses on the discovery, development, production and commercialization of pharmaceuticals and biotechnology products. The company offers drugs in the areas of nephrology, oncology, immunology and allergy, central nervous system among others. Its development pipeline consists of various protein, antibody and small molecule formulations for the treatment of neutropenia, anemia, chronic idiopathic thrombocytopenic purpura, hypertension, angina pectoris, allergic rhinitis, epilepsy, behavioral or personality disorders and others. The company operates through a network of subsidiaries in the US, Europe and Asia. Kyowa Kirin is headquartered in Tokyo, Japan.
Kyowa Kirin Co Ltd Key Recent Developments
Mar 25,2021: Twist Bioscience and Kyowa Kirin partner for GPCR antibody discovery
Feb 25,2021: Harvard University and Kyowa Kirin enter strategic research alliance
Feb 04,2021: Kyowa Kirin announces changes to its organization
Jan 02,2021: Axcelead and Kyowa Kirin started an innovative collaboration in small-molecule drug development
Oct 20,2020: Kyowa Kirin North America announces recipients of Patient Education grants to address disparities for African-American Patients with cutaneous T-Cell Lymphomas
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Kyowa Kirin Co Ltd (Kyowa Kirin), a subsidiary of Kirin Holdings Co Ltd, is a research and development based biotechnology company. It focuses on the discovery, development, production and commercialization of pharmaceuticals and biotechnology products. The company offers drugs in the areas of nephrology, oncology, immunology and allergy, central nervous system among others. Its development pipeline consists of various protein, antibody and small molecule formulations for the treatment of neutropenia, anemia, chronic idiopathic thrombocytopenic purpura, hypertension, angina pectoris, allergic rhinitis, epilepsy, behavioral or personality disorders and others. The company operates through a network of subsidiaries in the US, Europe and Asia. Kyowa Kirin is headquartered in Tokyo, Japan.
Kyowa Kirin Co Ltd Key Recent Developments
Mar 25,2021: Twist Bioscience and Kyowa Kirin partner for GPCR antibody discovery
Feb 25,2021: Harvard University and Kyowa Kirin enter strategic research alliance
Feb 04,2021: Kyowa Kirin announces changes to its organization
Jan 02,2021: Axcelead and Kyowa Kirin started an innovative collaboration in small-molecule drug development
Oct 20,2020: Kyowa Kirin North America announces recipients of Patient Education grants to address disparities for African-American Patients with cutaneous T-Cell Lymphomas
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
SECTION 1 - ABOUT THE COMPANY
Kyowa Kirin Co Ltd - Key Facts
Kyowa Kirin Co Ltd - Key Employees
Kyowa Kirin Co Ltd - Key Employee Biographies
Kyowa Kirin Co Ltd - Major Products and Services
Kyowa Kirin Co Ltd - History
Kyowa Kirin Co Ltd - Company Statement
Kyowa Kirin Co Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
SECTION 2 – COMPANY ANALYSIS
Company Overview
Kyowa Kirin Co Ltd - Business Description
Geographical Segment: Americas
Performance
Geographical Segment: Asia
Performance
Geographical Segment: Europe
Performance
Geographical Segment: Japan
Performance
Geographical Segment: Other
Performance
R&D Overview
Kyowa Kirin Co Ltd - Corporate Strategy
Kyowa Kirin Co Ltd - SWOT Analysis
SWOT Analysis - Overview
Kyowa Kirin Co Ltd - Strengths
Kyowa Kirin Co Ltd - Weaknesses
Kyowa Kirin Co Ltd - Opportunities
Kyowa Kirin Co Ltd - Threats
Kyowa Kirin Co Ltd - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
Kyowa Kirin Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Kyowa Kirin Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Kyowa Kirin Co Ltd, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
Mar 25, 2021: Twist Bioscience and Kyowa Kirin partner for GPCR antibody discovery
Feb 25, 2021: Harvard University and Kyowa Kirin enter strategic research alliance
Feb 04, 2021: Kyowa Kirin announces changes to its organization
Jan 02, 2021: Axcelead and Kyowa Kirin started an innovative collaboration in small-molecule drug development
Oct 20, 2020: Kyowa Kirin North America announces recipients of Patient Education grants to address disparities for African-American Patients with cutaneous T-Cell Lymphomas
Jul 13, 2020: Kyowa Kirin announces patient education grant program to address disparities for African American patients with cutaneous t-cell lymphomas (CTCL)
Jun 29, 2020: Kyowa Kirin names Finance Executive Ana Bastiani-Posner as Executive Vice President, Chief Financial Officer, North America
Feb 05, 2020: Kyowa Kirin announces its organization changes
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
Kyowa Kirin Co Ltd - Key Facts
Kyowa Kirin Co Ltd - Key Employees
Kyowa Kirin Co Ltd - Key Employee Biographies
Kyowa Kirin Co Ltd - Major Products and Services
Kyowa Kirin Co Ltd - History
Kyowa Kirin Co Ltd - Company Statement
Kyowa Kirin Co Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
SECTION 2 – COMPANY ANALYSIS
Company Overview
Kyowa Kirin Co Ltd - Business Description
Geographical Segment: Americas
Performance
Geographical Segment: Asia
Performance
Geographical Segment: Europe
Performance
Geographical Segment: Japan
Performance
Geographical Segment: Other
Performance
R&D Overview
Kyowa Kirin Co Ltd - Corporate Strategy
Kyowa Kirin Co Ltd - SWOT Analysis
SWOT Analysis - Overview
Kyowa Kirin Co Ltd - Strengths
Kyowa Kirin Co Ltd - Weaknesses
Kyowa Kirin Co Ltd - Opportunities
Kyowa Kirin Co Ltd - Threats
Kyowa Kirin Co Ltd - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
Kyowa Kirin Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Kyowa Kirin Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Kyowa Kirin Co Ltd, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
Mar 25, 2021: Twist Bioscience and Kyowa Kirin partner for GPCR antibody discovery
Feb 25, 2021: Harvard University and Kyowa Kirin enter strategic research alliance
Feb 04, 2021: Kyowa Kirin announces changes to its organization
Jan 02, 2021: Axcelead and Kyowa Kirin started an innovative collaboration in small-molecule drug development
Oct 20, 2020: Kyowa Kirin North America announces recipients of Patient Education grants to address disparities for African-American Patients with cutaneous T-Cell Lymphomas
Jul 13, 2020: Kyowa Kirin announces patient education grant program to address disparities for African American patients with cutaneous t-cell lymphomas (CTCL)
Jun 29, 2020: Kyowa Kirin names Finance Executive Ana Bastiani-Posner as Executive Vice President, Chief Financial Officer, North America
Feb 05, 2020: Kyowa Kirin announces its organization changes
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
LIST OF TABLES
Kyowa Kirin Co Ltd, Key Facts
Kyowa Kirin Co Ltd, Key Employees
Kyowa Kirin Co Ltd, Key Employee Biographies
Kyowa Kirin Co Ltd, Major Products and Services
Kyowa Kirin Co Ltd, History
Kyowa Kirin Co Ltd, Other Locations
Kyowa Kirin Co Ltd, Subsidiaries
Kyowa Kirin Co Ltd, Joint Venture
Kyowa Kirin Co Ltd, Key Competitors
Kyowa Kirin Co Ltd, Ratios based on current share price
Kyowa Kirin Co Ltd, Annual Ratios
Kyowa Kirin Co Ltd, Annual Ratios (Cont...1)
Kyowa Kirin Co Ltd, Annual Ratios (Cont...2)
Kyowa Kirin Co Ltd, Interim Ratios
Kyowa Kirin Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Kyowa Kirin Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Kyowa Kirin Co Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
Kyowa Kirin Co Ltd, Key Facts
Kyowa Kirin Co Ltd, Key Employees
Kyowa Kirin Co Ltd, Key Employee Biographies
Kyowa Kirin Co Ltd, Major Products and Services
Kyowa Kirin Co Ltd, History
Kyowa Kirin Co Ltd, Other Locations
Kyowa Kirin Co Ltd, Subsidiaries
Kyowa Kirin Co Ltd, Joint Venture
Kyowa Kirin Co Ltd, Key Competitors
Kyowa Kirin Co Ltd, Ratios based on current share price
Kyowa Kirin Co Ltd, Annual Ratios
Kyowa Kirin Co Ltd, Annual Ratios (Cont...1)
Kyowa Kirin Co Ltd, Annual Ratios (Cont...2)
Kyowa Kirin Co Ltd, Interim Ratios
Kyowa Kirin Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Kyowa Kirin Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Kyowa Kirin Co Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
LIST OF FIGURES
Kyowa Kirin Co Ltd, Performance Chart (2016 - 2020)
Kyowa Kirin Co Ltd, Ratio Charts
Kyowa Kirin Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Kyowa Kirin Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021
Kyowa Kirin Co Ltd, Performance Chart (2016 - 2020)
Kyowa Kirin Co Ltd, Ratio Charts
Kyowa Kirin Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Kyowa Kirin Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021